The Newer Term for ITP
The abbreviation ITP now stands for "immune thrombocytopenia" or "immune thrombocytopenic purpura" rather than the older term "idiopathic thrombocytopenic purpura." 1
Rationale for the Terminology Change
The shift in terminology reflects two important clinical realities:
Recognition of immune-mediated pathophysiology: The disease is now understood to be an acquired immune-mediated disorder, not simply "idiopathic" (of unknown cause). The mechanisms involve autoantibodies against platelet surface proteins, impaired platelet production, and T cell-mediated effects 1
Absence of purpura in many patients: A large proportion of patients with ITP have minimal or no bleeding signs, making "purpura" an inaccurate descriptor for the disease spectrum 1
Current Terminology in Practice
The most recent American Society of Hematology 2019 guidelines use "immune thrombocytopenia" as the preferred term, maintaining the ITP abbreviation 2. This terminology has been standard since the 2010 International Consensus Report, which formally revised the nomenclature 1.
The term "primary immune thrombocytopenia" is used when ITP occurs without any obvious underlying cause, while "secondary ITP" refers to thrombocytopenia associated with other autoimmune conditions, infections, or immunodeficiencies 2, 1.